A Phase 2 interventional study of LY3473329 and Placebo in Lipoprotein Disorder, sponsored by Eli Lilly and Company. Completed at 42 sites in 8 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-03-25.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Atherosclerosis by Eli Lilly and Company — 5 open to participants now, 7 under way, 4 of them phase 3. Atherosclerosis · Eli Lilly and Company.
Among the 10 studies in Atherosclerosis by Eli Lilly and Company, this one is one of 2 that started in 2022, is one of 4 in phase 2, and was the 3rd registered.
1,519 studies on the registry are indexed under Atherosclerosis; 225 are open to participants now.
Browse Atherosclerosis studies →5 of the 10 studies in Atherosclerosis by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Verve Therapeutics, Inc. · Sites in United States
Ages 18–70
Eli Lilly and Company · Sites in United States, Argentina, Japan and 1 more country
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Czechia and 4 more countries
Ages 45–80
Eli Lilly and Company · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
Verve Therapeutics, Inc. · Sites in New Zealand, United Kingdom
Ages 18+
By country, each count listing its studies:
Of the 161 Atherosclerosis studies recruiting now, 84 (52%) set no upper age limit and 33 (20%) stop at 75 or younger; 16 take children under 18; 33 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 233 is above the median of 100 across 880 interventional studies indexed under Atherosclerosis.
Median enrollment 252 across the 9 interventional studies, 116 across the 1 observational. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
1 of the studies in Atherosclerosis by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07783802Eli Lilly and CompanyA Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Atherosclerosis by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lp(a) at high risk for cardiovascular events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants on the following medications according to local practice must be on a stable regimen for at least 4 weeks prior to randomization and expected to remain on a stable regimen through the end of the post-treatment follow-up period.
Exclusion Criteria:
Any of the following, or other events indicating unstable medical condition in the opinion of the investigator, within 3 months of randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 10 milligrams (mg) of LY3473329 administered orally once daily (QD) over a 12-week treatment period.
Drug: LY3473329
Participants received 60 mg of LY3473329 administered orally QD over a 12-week treatment period.
Drug: LY3473329
Participants received 240 mg of LY3473329 administered orally QD over a 12-week treatment period.
Drug: LY3473329
Participants received a matching dose of placebo administered orally QD over a 12-week treatment period.
Drug: Placebo
Administered orally
Administered orally
Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay
Least Squares Mean (LS Mean) was calculated using a Mixed Model for Repeated Measures (MMRM): Log (Actual Measurement/Baseline) = Log (Baseline) + Country + Treatment + Time + Treatment\*Time.
Time frame: Baseline, Week 12
Percent Change From Baseline in Lp(a) - Assessed Via Apo(a) Assay
LS Mean was calculated using a MMRM: Log (Actual Measurement/Baseline) = Log (Baseline) + Country + Treatment + Time + Treatment\*Time.
Time frame: Baseline, Week 12
Percentage of Participants Who Achieved Lp(a) < 125 Nmol/L - Assessed Via Intact Lp(a) Assay
The percentage of participants who achieved Lp(a) less than (\<) 125 nmol/L, as measured using the intact Lp(a) assay, with data analysis performed through a logistic regression model that included imputed missing values, was reported.
Time frame: Week 12
Percentage of Participants Who Achieved Lp(a) < 125 Nmol/L - Assessed Via Apo(a) Assay
The percentage of participants who achieved Lp(a) \< 125 nmol/L, as measured using the apo(a) assay, with data analysis performed through a logistic regression model that included imputed missing values, was reported.
Time frame: Week 12
Percent Change From Baseline in Apolipoprotein B (ApoB)
LS Mean was calculated using a MMRM: Log (Actual Measurement/Baseline) = Log (Baseline) + Country + Baseline Lp(a) Stratum + Treatment + Time + Treatment\*Time.
Time frame: Baseline, Week 12
Percent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
LS Mean was calculated using a MMRM: Log (Actual Measurement/Baseline) = Log (Baseline) + Country + Baseline Lp(a) Stratum + Treatment + Time + Treatment\*Time.
Time frame: Baseline, Week 12
Pharmacokinetics (PK): Trough Concentrations (C-trough) of LY3473329
C-trough were measured at specified time points to assess the minimum concentration of LY3473329 in the blood before the next dose was administered.
Time frame: Week from randomization 1, 2, 8, 12: Pre-dose
| Milestone | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo |
|---|---|---|---|---|
| Started | 34 | 64 | 68 | 67 |
| Received at least one dose of study drug | 34 | 63 | 68 | 67 |
| Completed | 33 | 60 | 65 | 67 |
| Not completed | 1 | 4 | 3 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
Least Squares Mean (LS Mean) was calculated using a Mixed Model for Repeated Measures (MMRM): Log (Actual Measurement/Baseline) = Log (Baseline) + Country + Treatment + Time + Treatment\*Time.
| Percent change | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay | -47.35 ± 4.811 | -81.57 ± 1.230 | -85.71 ± 0.927 | 0.48 ± 6.382 |
LS Mean was calculated using a MMRM: Log (Actual Measurement/Baseline) = Log (Baseline) + Country + Treatment + Time + Treatment\*Time.
| Percent change | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline in Lp(a) - Assessed Via Apo(a) Assay | -42.26 ± 4.477 | -70.90 ± 1.669 | -69.88 ± 1.676 | -3.15 ± 5.342 |
The percentage of participants who achieved Lp(a) less than (\<) 125 nmol/L, as measured using the intact Lp(a) assay, with data analysis performed through a logistic regression model that included imputed missing values, was reported.
| Percentage of participants | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Achieved Lp(a) < 125 Nmol/L - Assessed Via Intact Lp(a) Assay | 69.6 | 95.6 | 95.7 | 6.1 |
The percentage of participants who achieved Lp(a) \< 125 nmol/L, as measured using the apo(a) assay, with data analysis performed through a logistic regression model that included imputed missing values, was reported.
| Percentage of participants | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo |
|---|---|---|---|---|
| Percentage of Participants Who Achieved Lp(a) < 125 Nmol/L - Assessed Via Apo(a) Assay | 37.9 | 82.1 | 77.2 | 3.3 |
LS Mean was calculated using a MMRM: Log (Actual Measurement/Baseline) = Log (Baseline) + Country + Baseline Lp(a) Stratum + Treatment + Time + Treatment\*Time.
| Percent change | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (ApoB) | -10.49 ± 4.349 | -14.53 ± 3.055 | -17.56 ± 2.877 | -1.70 ± 3.362 |
LS Mean was calculated using a MMRM: Log (Actual Measurement/Baseline) = Log (Baseline) + Country + Baseline Lp(a) Stratum + Treatment + Time + Treatment\*Time.
| Percent change | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) | 21.87 ± 20.029 | -2.41 ± 11.713 | -15.39 ± 9.921 | -9.91 ± 10.526 |
C-trough were measured at specified time points to assess the minimum concentration of LY3473329 in the blood before the next dose was administered.
| nanograms per milliliter (ng/mL) | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 |
|---|---|---|---|
| Week 1 | 13.0 ± 81 | 42.4 ± 79 | 83.3 ± 70 |
| Week 2 | 14.8 ± 73 | 39.3 ± 76 | 77.9 ± 62 |
| Week 8 | 14.5 ± 67 | 38.8 ± 89 | 73.9 ± 110 |
| Week 12 | 15.4 ± 64 | 37.7 ± 95 | 74.0 ± 111 |
Collected over Baseline to end of follow-up (up to 16 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 10 mg LY3473329 | 0/34 (0%) | 2/34 (5.9%) | 7/34 (20.6%) |
| 60 mg LY3473329 | 0/63 (0%) | 2/63 (3.2%) | 5/63 (7.9%) |
| 240 mg LY3473329 | 0/68 (0%) | 2/68 (2.9%) | 10/68 (14.7%) |
| Placebo | 0/67 (0%) | 4/67 (6%) | 11/67 (16.4%) |
| Event | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo |
|---|---|---|---|---|
| Lower limb fractureInjury, poisoning and procedural complications | 1/34 | 0/63 | 0/68 | 0/67 |
| BursitisMusculoskeletal and connective tissue disorders | 1/34 | 0/63 | 0/68 | 0/67 |
| PriapismReproductive system and breast disorders | 0/23 | 0/41 | 1/44 | 0/48 |
| Atrial fibrillationCardiac disorders | 0/34 | 1/63 | 0/68 | 0/67 |
| DizzinessNervous system disorders | 0/34 | 1/63 | 0/68 | 0/67 |
| SyncopeNervous system disorders | 0/34 | 1/63 | 0/68 | 0/67 |
| ConcussionInjury, poisoning and procedural complications | 0/34 | 0/63 | 0/68 | 1/67 |
| Wrist fractureInjury, poisoning and procedural complications | 0/34 | 0/63 | 0/68 | 1/67 |
| Peripheral arterial occlusive diseaseVascular disorders | 0/34 | 0/63 | 0/68 | 1/67 |
| Peripheral vascular haematomaVascular disorders | 0/34 | 0/63 | 0/68 | 1/67 |
| Event | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/34 | 1/63 | 4/68 | 4/67 |
| AnaemiaBlood and lymphatic system disorders | 2/34 | 0/63 | 0/68 | 0/67 |
| NauseaGastrointestinal disorders | 2/34 | 1/63 | 0/68 | 3/67 |
| InfluenzaInfections and infestations | 2/34 | 1/63 | 1/68 | 1/67 |
| OverdoseInjury, poisoning and procedural complications | 0/34 | 2/63 | 4/68 | 1/67 |
| Back painMusculoskeletal and connective tissue disorders | 2/34 | 0/63 | 0/68 | 2/67 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/34 | 1/63 | 1/68 | 0/67 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/11 | 0/22 | 0/24 | 1/19 |
All randomized participants.
| Age, Continuous(years) | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 64.06 ± 10.01 | 65.50 ± 9.36 | 64.75 ± 9.35 | 62.78 ± 9.93 | 64.29 ± 9.61 |
| Sex: Female, Male(Participants) | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo | Total |
|---|---|---|---|---|---|
| Female | 11 | 22 | 24 | 19 | 76 |
| Male | 23 | 42 | 44 | 48 | 157 |
| Ethnicity (NIH/OMB)(Participants) | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 11 | 10 | 9 | 34 |
| Not Hispanic or Latino | 30 | 50 | 57 | 58 | 195 |
| Unknown or Not Reported | 0 | 3 | 1 | 0 | 4 |
| Race (NIH/OMB)(Participants) | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 9 | 17 | 19 | 18 | 63 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 2 | 5 | 1 | 1 | 9 |
| White | 22 | 41 | 45 | 45 | 153 |
| More than one race | 0 | 1 | 3 | 3 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo | Total |
|---|---|---|---|---|---|
| Australia | 6 | 12 | 12 | 12 | 42 |
| Brazil | 6 | 13 | 12 | 12 | 43 |
| China | 4 | 8 | 9 | 9 | 30 |
| Germany | 4 | 5 | 8 | 7 | 24 |
| Hungary | 6 | 11 | 11 | 11 | 39 |
| Japan | 4 | 8 | 8 | 9 | 29 |
| Netherlands | 2 | 3 | 3 | 4 | 12 |
| United States | 2 | 4 | 5 | 3 | 14 |
| Lp(a) - Assessed via Intact Lp(a) Assay(nanomoles per liter (nmol/L)) | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 220.99 ± 60.39 | 223.47 ± 97.36 | 242.42 ± 100.18 | 250.53 ± 96.66 | 236.63 ± 93.74 |
| Lp(a) - Assessed via Apo(a) Assay(nanomoles per liter (nmol/L)) | 10 mg LY3473329 | 60 mg LY3473329 | 240 mg LY3473329 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 269.67 ± 78.10 | 256.28 ± 96.55 | 273.84 ± 90.68 | 265.30 ± 85.80 | 265.99 ± 88.93 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Nov 2022 to primary completion in Mar 2024, 15 months.
Results were first posted in Mar 2025, 1 year after primary completion.
Of 46 phase 2 interventional studies under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Muvalaplin